I've spent nearly all my working life as a journalist. I covered the rise and fall of the dot-com era in the second half of the 1990s, then switched to life sciences in the new millennium. I've written about the strategy, financing and scientific breakthroughs of biotech for The Deal, Elsevier's Start-Up, In Vivo and The Pink Sheet, and now Xconomy.
Natera of San Carlos, CA, has bumped the fundraising goal for its upcoming IPO to $175 million, according to a document filed today with the Securities and Exchange Commission. The maker... Read more »
If you’re an investor anticipating the potential $100 million-plus IPO of microbiome company Seres Therapeutics, your wait should be over before the weekend comes. If you’re a patient with a terrible... Read more »
By now you’ve had a day or two to meet Exome, Xconomy’s new place for all things life sciences, health, and biotech, which launched Monday. Let me amend that. Some things... Read more »
We’re sharing everything these days. Rides. Spare rooms. Pictures of things wrapped in bacon. Our thoughts, 24 hours a day. Next up: Cancer data?
It can’t come soon enough for Charles... Read more »
[UPDATED: 6/19/15, 3:53pm. See below.] There are several long-term studies taking place around the world to track the health of large groups of people. One in Seattle called the... Read more »
[Corrected 6/17/15, 12:30pm. See below.] CytomX Therapeutics is crossing over in more ways than one.
With the help of investors who typically make bets on the public side of... Read more »
The Fred Hutchinson Cancer Research Center in Seattle said today it has hired a new chief information officer, Matthew Trunnell, as the biomedical institution moves into an era of deep genomic... Read more »
We fly, you buy. That’s been the formula for the Avalon Ventures-GlaxoSmithKline biotech collaboration, with Avalon scouting for ideas around the country and GSK bankrolling them into startups that it can... Read more »
The biggest West Coast news happened near the nation’s capital this week. Amgen (NASDAQ: AMGN) of Thousand Oaks, CA, saw its next-generation anti-cholesterol drug evolocumab (Repatha) get a thumbs-up, with... Read more »
[Corrected 6/10/15, 10:14pm. See below.] Katherine Wilemon had a celebratory glass of wine a couple hours ago, which some say is good for the heart. Even better for Wilemon, however,... Read more »
One down, one to go, and a lot of questions left unanswered. A panel of FDA advisors voted 13-3 today to recommend that the agency give the green light to alirocumab... Read more »
My mother always warned me never to start a column with a reference to management consultants. Sorry, Mom. Cover your eyes. But anyone else with personal health or personal finance interest... Read more »
While a big slice of the oncology world was packed into a Chicago conference center earlier this week for the American Society for Clinical Oncology conference, other news happened, too.... Read more »
As has been the case the past few years, the annual American Society of Clinical Oncology meeting, which just wrapped up in Chicago, was the latest referendum on immunotherapy. But this... Read more »
In March, independent investor Brad Loncar unveiled a homebrewed stock index, created to track the red-hot cancer immunotherapy field. If he gets his way, there will soon be a publicly traded... Read more »
© 2007-2015, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.